Unassociated Document
 
 
United States Securities And Exchange Commission
Washington, DC 20549
 
FORM 8-K/A
 
Amendment No. 1
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of Earliest Event Reported):  August 19, 2011
(June 1, 2011)
ISORAY, INC.
(Exact name of registrant as specified in its charter)

Minnesota
(State or other jurisdiction
of incorporation)
001-33407
(Commission
File Number)
41-1458152
(IRS Employer
Identification No.)

350 Hills Street, Suite 106, Richland, Washington 99354
 (Address of principal executive offices) (Zip Code)

(509) 375-1202
(Registrant's telephone number)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
   
o
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
   
o
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
   
o
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 

 
 
ITEM 1.01  Entry into a Material Definitive Agreement
 
This Amendment No. 1 (the "Amendment") to the Form 8-K filed on June 7, 2011 (the "Original 8-K") is filed solely to provide Annexures A and B in Exhibit 10.66. The remainder of the Original 8-K remains unchanged by this Amendment.
 
ITEM 9.01  Exhibits
 
 
(c) 
Exhibits
 
 
10.66
License Agreement, dated effective June 1, 2011, by and between IsoRay Medical, Inc. and Dr. Reddy's Laboratories (EU) Ltd. (confidential treatment requested for redacted portions)
 
SIGNATURES
 
In accordance with the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Dated:  August 19, 2011
 
 
IsoRay, Inc., a Minnesota corporation
 
     
       
 
By:
/s/ Dwight Babcock  
   
Dwight Babcock, CEO